GlycoMimetics (GLYC) Competitors $0.18 -0.01 (-2.76%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$0.18 0.00 (-0.56%) As of 04/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GLYC vs. ZIVO, SCLX, IKNA, UNCY, OKUR, CRVO, MURA, IOBT, INCR, and CUEShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include ZIVO Bioscience (ZIVO), Scilex (SCLX), Ikena Oncology (IKNA), Unicycive Therapeutics (UNCY), OnKure Therapeutics (OKUR), CervoMed (CRVO), Mural Oncology (MURA), IO Biotech (IOBT), InterCure (INCR), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. ZIVO Bioscience Scilex Ikena Oncology Unicycive Therapeutics OnKure Therapeutics CervoMed Mural Oncology IO Biotech InterCure Cue Biopharma GlycoMimetics (NASDAQ:GLYC) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is GLYC or ZIVO more profitable? ZIVO Bioscience's return on equity of 0.00% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -230.74% -177.39% ZIVO Bioscience N/A N/A -2,240.92% Which has higher valuation and earnings, GLYC or ZIVO? ZIVO Bioscience has higher revenue and earnings than GlycoMimetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K1,161.25-$37.88MN/AN/AZIVO Bioscience$15.85K3,728.09-$7.78M-$4.28-3.68 Which has more volatility & risk, GLYC or ZIVO? GlycoMimetics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Does the MarketBeat Community favor GLYC or ZIVO? GlycoMimetics received 218 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. However, 60.74% of users gave ZIVO Bioscience an outperform vote while only 58.17% of users gave GlycoMimetics an outperform vote. CompanyUnderperformOutperformGlycoMimeticsOutperform Votes31758.17% Underperform Votes22841.83% ZIVO BioscienceOutperform Votes9960.74% Underperform Votes6439.26% Do analysts rate GLYC or ZIVO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25ZIVO Bioscience 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to GLYC or ZIVO? In the previous week, GlycoMimetics had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for GlycoMimetics and 0 mentions for ZIVO Bioscience. GlycoMimetics' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score. Company Overall Sentiment GlycoMimetics Neutral ZIVO Bioscience Neutral Do institutionals and insiders believe in GLYC or ZIVO? 75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryGlycoMimetics beats ZIVO Bioscience on 7 of the 13 factors compared between the two stocks. Remove Ads Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.61M$6.35B$5.26B$7.12BDividend YieldN/A2.84%4.89%4.07%P/E RatioN/A6.8321.3817.50Price / Sales1,161.25187.44355.3289.02Price / CashN/A65.6738.1834.64Price / Book2.255.576.233.79Net Income-$37.88M$141.89M$3.21B$247.48M7 Day Performance-17.51%-11.51%-8.47%-6.79%1 Month Performance-32.63%-16.59%-4.87%-11.52%1 Year Performance-93.45%-18.14%2.54%-7.82% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics1.1854 of 5 stars$0.18-2.8%N/A-93.4%$11.61M$10,000.000.0050News CoverageGap DownZIVOZIVO BioscienceN/A$18.00+5.3%N/A+97.4%$67.30M$15,850.00-3.6910SCLXScilex1.8965 of 5 stars$0.28-1.5%$14.00+4,972.5%-83.1%$67.15M$55.15M-0.3380Analyst ForecastNews CoverageIKNAIkena Oncology1.9873 of 5 stars$1.39+1.5%$3.00+115.8%-16.9%$67.08M$659,000.00-1.1370News CoverageGap DownUNCYUnicycive Therapeutics2.5875 of 5 stars$0.64-5.4%$5.33+729.3%-64.7%$66.75M$680,000.00-0.669Analyst ForecastAnalyst RevisionNews CoverageOKUROnKure Therapeutics3.0657 of 5 stars$4.96-1.8%$32.33+551.9%N/A$66.64MN/A-0.41N/APositive NewsGap DownCRVOCervoMed2.9764 of 5 stars$10.71-25.1%$27.50+156.8%-48.8%$66.08M$7.14M-5.284Gap UpHigh Trading VolumeMURAMural Oncology2.4148 of 5 stars$3.83-0.5%$16.00+317.8%-75.4%$65.98MN/A-0.42119Gap DownIOBTIO Biotech2.8446 of 5 stars$1.00+4.2%$9.33+833.3%-39.6%$65.88MN/A-0.7330Analyst ForecastAnalyst RevisionNews CoverageGap DownINCRInterCure0.2539 of 5 stars$1.44-3.4%N/A-49.4%$65.63M$272.67M0.00350CUECue Biopharma4.3116 of 5 stars$1.03+4.6%$4.75+361.2%-62.1%$65.25M$9.53M-1.1460Earnings Report Remove Ads Related Companies and Tools Related Companies ZIVO Bioscience Alternatives Scilex Alternatives Ikena Oncology Alternatives Unicycive Therapeutics Alternatives OnKure Therapeutics Alternatives CervoMed Alternatives Mural Oncology Alternatives IO Biotech Alternatives InterCure Alternatives Cue Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLYC) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLYC Stock Free GLYC Stock Alerts